Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
NCT07181161
This study is recruiting at 9 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 130 years
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- September 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arkansas · 1
- Research Site · Fayetteville, AR
California · 1
- Research Site · Los Angeles, CA
Massachusetts · 1
- Research Site · Boston, MA
Michigan · 2
- Research Site · Ann Arbor, MI
- Research Site · Detroit, MI
New York · 1
- Research Site · New York, NY
Rhode Island · 1
- Research Site · Providence, RI
South Carolina · 1
- Research Site · Myrtle Beach, SC
Texas · 1
- Research Site · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.